Detalles de la búsqueda
1.
Recurrent SMARCB1 Mutations Reveal a Nucleosome Acidic Patch Interaction Site That Potentiates mSWI/SNF Complex Chromatin Remodeling.
Cell
; 179(6): 1342-1356.e23, 2019 11 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-31759698
2.
Publisher Correction: The metabolite BH4 controls T cell proliferation in autoimmunity and cancer.
Nature
; 572(7769): E18, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31363232
3.
The metabolite BH4 controls T cell proliferation in autoimmunity and cancer.
Nature
; 563(7732): 564-568, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30405245
4.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 24(12): 1359-1374, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37926100
5.
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Breast Cancer Res Treat
; 199(1): 35-46, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36859649
6.
Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking.
Hum Mol Genet
; 29(2): 320-334, 2020 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31915823
7.
The antigenic link between thyroid autoimmunity and breast cancer.
Semin Cancer Biol
; 64: 122-134, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31128301
8.
Modified Needleman-Wunsch algorithm for clinical pathway clustering.
J Biomed Inform
; 115: 103668, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33359110
9.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 18(7): 929-945, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28600210
10.
Lack of motor recovery after prolonged denervation of the neuromuscular junction is not due to regenerative failure.
Eur J Neurosci
; 43(3): 451-62, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26332731
11.
3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.
BMC Cancer
; 16: 345, 2016 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27251376
12.
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.
Ann Oncol
; 26(7): 1340-6, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26003169
13.
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Lancet Oncol
; 15(1): 114-22, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24332514
14.
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Lancet Oncol
; 15(9): 997-1006, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25035292
15.
Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.
Br J Cancer
; 110(8): 2139-43, 2014 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24691421
16.
Breast-cancer adjuvant therapy with zoledronic acid.
N Engl J Med
; 365(15): 1396-405, 2011 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-21995387
17.
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.
Breast Cancer Res Treat
; 144(2): 331-41, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24519386
18.
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
Lancet Oncol
; 14(10): 962-70, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23965225
19.
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Lancet Oncol
; 14(12): 1216-25, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24095299
20.
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Lancet Oncol
; 14(11): 1086-1094, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24055415